Title:A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient
Treated with Guselkumab
Volume: 17
Issue: 4
Author(s): Matteo Megna, Gabriella Fabbrocini, Lucia Gallo, Angela Patrì and Angelo Ruggiero*
Affiliation:
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy
Keywords:
Psoriasis, anti-IL-23, guselkumab, hepatitis C, hepatitis C reactivation, PASI.
Abstract:
Introduction: Psoriasis is a chronic inflammatory skin disease requiring long-term
treatment. However, there are approximately 71 million individuals with chronic HCV infection
worldwide. In psoriatic patients affected by chronic HCV infection, conventional systemic drugs
may be frequently contraindicated, while data on biologics use are limited.
Case Presentation: The case of a 48-year-old Caucasian man suffering from a severe form of
plaque psoriasis and affected by a chronic-HCV-infection treated with guselkumab has been reported.
Despite a huge improvement of the skin lesions (PASI reduced from 18 to 2), guselkumab
was discontinued due to an HCV-infection reactivation after 3 months of treatment.
Conclusion: To the best of our knowledge, this is the first case report of the use of guselkumab in
an HCV psoriatic patient. Further studies are needed to evaluate the safety of guselkumab in chronic
HCV patients.
